Dose Modeling in Ovarian Stimulation: Clinical Relevance, Evidence, and Practical Implications for Reproductive Medicine

Abstract

Ovarian stimulation is a cornerstone of assisted reproductive technology (ART), with dosing strategies critically impacting both efficacy and safety. Dose modeling seeks to personalize stimulation protocols by integrating patient-specific variables, aiming to optimize oocyte yield, minimize adverse effects, and improve live birth rates. This review synthesizes the current evidence on dose modeling in ovarian stimulation, explores the underlying mechanisms, evaluates clinical predictors, and discusses recent advances and guideline-based recommendations for individualized care.

Introduction

Controlled ovarian stimulation (COS) is integral to in vitro fertilization (IVF) and related ART procedures. The primary goals are to recruit multiple mature follicles, maximize oocyte retrieval, and enhance pregnancy rates while minimizing risks such as ovarian hyperstimulation syndrome (OHSS) and excessive cost. Traditional "one-size-fits-all" dosing regimens have evolved towards dose modeling, which utilizes patient-specific predictors to guide individualized gonadotropin dosing. This paradigm shift is underpinned by growing evidence that tailored stimulation regimens can improve outcomes and reduce complications. This article reviews the rationale, methodologies, and clinical impact of dose modeling in ovarian stimulation, with an emphasis on recent advances and guideline updates relevant to reproductive endocrinology practice.

Epidemiology / Disease Burden

Infertility affects an estimated 8–12% of reproductive-aged couples globally, with ovarian dysfunction and suboptimal follicular response contributing significantly to ART failure. Inadequate or excessive ovarian response to stimulation can result in poor oocyte yield or OHSS, respectively, both of which compromise clinical outcomes. The variability in ovarian response underscores the need for dose modeling to address the heterogeneous burden of infertility and optimize resource utilization in ART programs worldwide.

Pathophysiology

The ovarian response to exogenous gonadotropins is governed by complex interactions among follicular reserve, gonadotropin sensitivity, and endogenous hormonal milieu. Key determinants include the size of the antral follicle cohort, granulosa cell FSH receptor expression, and intra-ovarian paracrine factors. Individual variability in these mechanisms accounts for the wide spectrum of responses—from poor to hyper-responders—necessitating dose modeling to achieve a physiological and safe follicular recruitment.

Risk Factors

Several patient-specific factors influence ovarian response and are integral to dose modeling algorithms. Age, body mass index (BMI), ovarian reserve markers (anti-Müllerian hormone [AMH], antral follicle count [AFC]), baseline FSH, and prior response to stimulation are the most validated predictors. Genetic polymorphisms (e.g., FSH receptor variants) are emerging as additional determinants. Recognizing and quantifying these risk factors enables stratification of patients into anticipated response categories for tailored stimulation strategies.

Clinical Features

Clinical features of suboptimal ovarian response include retrieval of fewer than expected mature oocytes, cycle cancellation, and suboptimal estradiol rise. Conversely, features of excessive response encompass rapid follicular development, markedly elevated estradiol, and clinical manifestations of OHSS. A nuanced understanding of these presentations is critical for real-time dose adjustments and for interpreting dose modeling outcomes in clinical practice.

Diagnosis

Diagnosis of ovarian response is based on dynamic monitoring of follicular growth via ultrasound and serial estradiol measurements during COS. Baseline assessment of ovarian reserve utilizing AMH and AFC forms the foundation of dose prediction models. Various nomograms and algorithms integrate these parameters to forecast optimal starting doses and adjust therapy in response to observed clinical features.

Treatment & Management

Management of ovarian stimulation involves selecting the appropriate gonadotropin type, dose, and protocol (e.g., long agonist, antagonist, or mild stimulation). Dose modeling utilizes validated tools—such as the CONSORT, ART Calculator, and POSEIDON criteria—to individualize initial dosing and modify regimens based on ongoing response. Strategies for poor responders may include higher starting doses, adjuvant therapies, or alternative stimulation protocols, while for high responders, a lower starting dose and the use of GnRH antagonists or agonist trigger are recommended to mitigate OHSS risk.

Recent Advances / Emerging Therapies

Recent advances in dose modeling include the integration of machine learning algorithms and artificial intelligence to improve prediction accuracy. Incorporation of genetic markers (e.g., FSHR and LHR gene variants) is being explored to further refine personalization. Real-time adaptive dosing, based on continuous hormonal and ultrasonographic feedback, represents a promising direction. Additionally, the development of long-acting gonadotropins and novel adjuvants offers expanded options for individualized management.

Guideline Recommendations

Recent guidelines from the European Society of Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM) emphasize the importance of individualized gonadotropin dosing based on ovarian reserve markers and clinical history. Both organizations endorse the use of validated dose prediction models and recommend ongoing monitoring with dose adjustment to optimize safety and efficacy. The use of lower starting doses in high-risk patients and consideration of GnRH antagonist protocols for OHSS prevention are strongly supported.

Conclusion

Dose modeling in ovarian stimulation represents a significant advancement in reproductive medicine, enabling clinicians to tailor therapy to individual patient characteristics and optimize ART outcomes. Ongoing research into genetic and molecular predictors, coupled with advances in computational modeling, holds promise for further improving the precision and safety of ovarian stimulation. Adherence to evidence-based, guideline-directed dose modeling strategies is essential for maximizing efficacy, minimizing complications, and advancing personalized reproductive care.